Supplemental Immunization

Activity
RATIONALE

– The Department of Health (DOH) is committed to protect the population

against serious and often fatal vaccine-preventable diseases, such as
measles, through provision of free vaccines and vaccination.

– The last measles mass immunization (MI) in 2014 the country had a
significant reduction in measles transmission in the following years.
However, measles cases have begun to spread in the last quarter of2017
leading to some significant outbreaks.
Current Measles Outbreak Data

– The Epidemiology Bureau showed that there were 4,168 measles cases
reported nationwide from January 01 to March 26, 2018.

– Out of the 4,168 reported cases, 723 were laboratory-confirmed measles with a
total of 13 deaths.

– Most of the confirmed cases came from regions XI (27.73%), ARMM (21.59%),
IX (14.32%), XII (10.45%), and X (10%)
Current Measles Outbreak Data

– Outbreak Response Immunization (ORI) is being implemented in affected

provinces however, the measles virus transmission continues to date.

*To address the sustained measles transmission, the DOH will be conducting
a National Measles Supplemental Immunization Activity(SIA), Phase 2 this
coming October,2018 for Luzon and Visayas
General Guidelines

Target Population :
– ALL infants and children 6—59 months old shall be given one dose of measles
vaccine, regardless of the immunization status.
Dosage and Route :
- 0.5 ml, subcutaneous at the left deltoid arm
Strategy :
- Fixed Points
- House to House Vaccination
VACCINE

Measles-containing vaccine (Measles-Rubella [MR], Measles, Mumps, and

Rubella [MMR])
- is a live-attenuated virus vaccine prequalified by WHO.
MR
- vaccine comes in 10-dose
MMR
– comes in 5 dose vial lyophilized powder requiring reconstitution with supplied
diluent for subcutaneous injection
MEASLES VACCINE

– are SAFE
– Adverse reactions following immunization (AEFI) of measles-containing vaccine
are generally mild and transient.
– Slight pain, tenderness, mild swelling, and redness at the injection site, mild
fever and local adenopathy may occur.
– Severe and systemic reactions following immunization with measles—
containing vaccine are RARE.
GENERAL CONTRAINDICATIONS

a) Severe hypersensitivity reaction to any vaccine component, including gelatin

b) Anaphylactic or anaphylactoid reactions to neomycin
c) Febrile respiratory illness or other febrile infection.
d) Patients receiving immunosuppressive or cancer treatment
e) Individuals with blood dyscracias, leukemia, lymphomas or other malignant
neoplasms affecting the bone marrow or lymphatic system
f) Primary and acquired immunodeficiency states
g) Individuals a family history of congenital or hereditary
immunodeficiency, until the immune competence is demonstrated
IMPORTANT NOTES

– As with all vaccines. measles containing vaccine may- not give 100% protection
to those who have been vaccinated.
– All infants and children given measles-containing vaccine from 6-8 months old
are considered MCVO and should be given another MCVl (MMR) dose at 9
months of age during the routine immunization.
– Onlv infants and children included eligible for vaccination with Measles
Containing Vaccine shall undergo a quick health check prior to vaccination
VACCINE STORAGE AND TRANSPORT

1. MMR and MR vaccines should be stored at +2°C to +8°C. This recommended

temperature shall be maintained during storage, transport and immunization
sessions.
2. The diluents may be stored in the refrigerator with the vaccine or separately at
room temperature. Do not freeze the diluents
3. Excess unopened vaccines brought in outreach areas shall be marked with a
check (/) before returning to the refrigerator for storage. The check mark
shall indicate the vaccine vial was out from the refrigerator. This shall be
prioritized for use in the next immunization session.
– 4. Protect the vaccine from the light at all times, since such exposure may
inactivate the vaccine
Vaccination Safety

1. Always follow the recommended schedule and the correct dosage, site and
route of vaccination
2. Always check the status of vaccine vial monitor (VVM) and expiration date
before opening a vaccine vial
3. Use only auto-disabled syringes in all immunization sessions
4. Use of aspirating needles and pre-filling of syringes are strictly prohibited
5. Do not recap used needles
6. Immediately dispose used syringes and needles into the safety collector box.
7. Used needles and syringes, empty vaccine vials, used cotton balls are
considered infectious and shall be disposed in the recommended appropriate
disposal of infectious/biological wastes
VACCINE STORAGE AND TRANSPORT

8. It is recommended that the vaccine be used as soon as possible after

reconstitution. Opened and reconstituted measles-containing vaccine shall be
discarded six (6) hours from reconstitution or at the end of immunization
period whichever comes first .Following the recommended disposal of the
biological waste.

Note:
Final disposal of safety collector box(es) with used needles and syringes
should follow the DOH recommended disposal for hazardous wastes
ADVERSE EVENTS FOLLOWING
IMMUNIZATIONS (AEFI)

Adverse events following immunization (AEFI) is defined as any untoward medical

occurrence which follows immunization and which does not necessarily have a
causal relationship with the usage of the vaccine.

1. The existing DOH guidelines, Administrative Order No. 2016-0006, on

AEFI surveillance and response shall be used for this purpose.
ADVERSE EVENTS FOLLOWING
IMMUNIZATIONS (AEFI)

2. As with all injectable vaccines, appropriate medical treatment should always

be readily available in case of rare anaphylactic reactions following
the administration of the vaccine occurs .
RECORDING AND REPORTING

The following forms shall be used:

a. Recording Form
– Form 1: Daily Tally Sheet

b. Reporting Forms
– Forms 1: DAILY REPORTING
– Form 2: WEEKLY CONSOLIDATION
FORM 1: DAILY TALLY SHEET

– RECORDING FORM 1 SIA.docx

REPORTING FORMS

Form 1 SIA.docx
REPORTING FORMS

– RECORDING FORM 2 SIA.docx.xlsx

RECORDING AND REPORTING OF
ACCOMPLISHMENT REPORTS

1. Each vaccination team should record each MCV dose given in the Recording
Form 1: Daily Tally Sheet and in the infant/child’s routine immunization
record.
2. The supplemental MCV dose shall be recorded under “Other vaccines”
RECORDING AND REPORTING OF ACCOMPLISHMENT
REPORTS

3. Duly accomplished reporting forms should be submitted to the next level for
review and consolidation following the standard reporting flow.
 RECORDING AND REPORTING OF
ACCOMPLISHMENT REPORTS

4. Weekly Accomplishment Reports shall be submitted by the DOH Regional

Offices to the DOH National Office every Friday before 3 PM.
Email Address: 201 8ligtastigdas@gmail.com

5. Submission of final accomplishment shall be 2 weeks after the conclusion of

the SIA
POST IMPLEMENTATION PHASE

RAPID COVERAGE ASSESSMENT